Stocks in play: Marvel Biosciences Corp

Announces that along with its wholly owned subsidiary, Marvel Biotechnology Inc., it has completed the dosing portion of the 4-week good laboratory practice FDA investigational new drug enabling dose-ranging dog and rat studies for its lead drug candidate MB-204. MB-204 is a fluorinated derivative of the U.S. FDA-approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. Caffeine consumption has been associated with a reduced risk of developing Parkinson's disease, and Alzheimer's disease and improved concentration. Marvel Biosciences Corp shares V.MRVL are trading unchanged at $0.10.

Read:

• Global Lithium Supply Under Pressure as South American Nations Discuss "Lithium OPEC"

• International Lithium Buyers Looking to South America to Fill Supply Gaps

• Race to Secure Critical EV Battery Metals Ahead of Chinese Dominance Fully Underway

• Help is on the Way as Rising Alzheimer’s Cases Highlight Urgency for New Treatments

• FDA’s Wave of Fast Track Designations Pushing Momentum in Healthcare Sector in 2023